| Trial ID # | NCT02659384; EORTC-1508 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-L1 |
| Drug Name | Atezolizumab |
| Alternate Drug Names | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A , MPDL3280A, RG7446 |
| Drugs in Trial | Acetylsalicylic acid, Atezolizumab, Bevacizumab |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 122; 70% w/ prior bevacizumab |
| Therapy Setting | Recurrence |
| Study Design | Double Blind, Randomized |
| Endpoints | ORR, PFS, TFST, evaluated per RECIST |
| Efficacy | Bev vs Bev+Ate vs Bev+Ate+Asa: ORR: 24.1 vs 20.7 vs 27.6% |
| Clinically Significant Adverse Events | Bev vs Bev+Ate vs Bev+Ate+Asa: |
| Conclusion | The addition of atezolizumab to bevacizumab (with or without acetylsalicylic acid) improves PFS and TFST |
| Reference | Banerjee S et al. Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma. Annals Oncol (2021) 32 (suppl_5): abstract LBA32 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.